Zhibao Technology Subsidiary Secures Major Insurance Brokerage Agreement for Health Project

summarizeZusammenfassung

The amended 20-F filing reveals a material cooperation agreement where Zhibao Technology's subsidiary, Sunshine Insurance Brokerage (Shanghai) Co., Ltd., will serve as the insurance brokerage service provider for a large-scale commercial health insurance project in China. This agreement, valid until December 31, 2025, outlines the subsidiary's role in consortium establishment, promotion, and client consultation, with a commission rate of 10.6% on collected premiums. Based on the project's target participation rate, this partnership could generate substantial annual commission revenue, significantly impacting the company's financial performance relative to its current market valuation. The disclosure of such a significant revenue-generating agreement, even retrospectively through an amendment, is a very positive development for the micro-cap company.

check_boxSchlusselereignisse

• Disclosure of Material Cooperation Agreement

  Zhibao Technology Inc. filed an amended 20-F to include a cooperation agreement for a significant commercial health insurance project in China.

• Subsidiary's Role as Broker

  The company's subsidiary, Sunshine Insurance Brokerage (Shanghai) Co., Ltd., will act as the insurance brokerage service provider for the '2025 Project' health insurance scheme.

• Significant Revenue Potential

  The agreement outlines a 10.6% brokerage commission on premiums for a project targeting millions of participants, indicating substantial potential annual revenue for the company.

• Consortium Structure

  The subsidiary is part of a co-insurance consortium involving multiple insurers and a technical service provider, highlighting a collaborative industry effort.

auto_awesomeAnalyse

The amended 20-F filing reveals a material cooperation agreement where Zhibao Technology's subsidiary, Sunshine Insurance Brokerage (Shanghai) Co., Ltd., will serve as the insurance brokerage service provider for a large-scale commercial health insurance project in China. This agreement, valid until December 31, 2025, outlines the subsidiary's role in consortium establishment, promotion, and client consultation, with a commission rate of 10.6% on collected premiums. Based on the project's target participation rate, this partnership could generate substantial annual commission revenue, significantly impacting the company's financial performance relative to its current market valuation. The disclosure of such a significant revenue-generating agreement, even retrospectively through an amendment, is a very positive development for the micro-cap company.